Prevalence of Exercise-induced Ventilatory Limitation and Associated Factors in Patients With Cystic Fibrosis Receiving Elexacaftor-Tezacaftor-Ivacaftor

Cystic fibrosis is a genetic disorder affecting the entire body and associated with respiratory exacerbations, impaired quality of life and reduced life expectancy. The therapeutic management of cystic fibrosis has been profoundly changed by the recent arrival of a combination of highly effective cystic fibrosis transmembrane conductance regulator (CFTR) modulators, Elexacaftor-Tezacaftor-Ivacaftor (ETI), which improve quality of life, respiratory function and reducing the number of exacerbations. The impact of these treatments on exercise adaptation has not been clearly identified. The main objective is to estimate the prevalence of ventilatory reserve amputation during submaximal exercise testing assessed by the 6-minute walk test (6MWT) in patients with cystic fibrosis treated with ETIs.

NCT Number	NCT07314229
Lead Sponsor	University Hospital, Lille Collaborators: Vaincre la Mucoviscidose
Conditions	Cystic Fibrosis (CF), Mucoviscidosis
Enrollment	130 participants
Start Date	2025-12-17
Primary Completion	2027-02-02 (estimated)
Study Completion	2027-04-04 (estimated)
Updated on ClinicalTrials.gov	2026-04-22